drugset / Trial / NCT00003746

Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia

NCT00003746

Phase 3 Completed 100 enrolled Swiss Cancer Institute
RandomizedFactorialOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if giving cladribine once a day is more effective than giving cladribine once a week in patients with hairy cell leukemia. PURPOSE: Randomized phase III trial to compare the effectiveness of cladribine given once a day to cladribine given once a week in treating patients with hairy cell leukemia.

Timeline

Start
1998-09
Primary completion
2005-11
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cladribine Small molecule 0.14 mg/kg Subcutaneous

Indications